QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A10F0BAC488BB1596C5F0CE4F667FB3F;jsessionid=4604EAF85061B7D2112CE838C4F764A6;jsessionid=F32A6229814EF0D0EEB5C0B14F6DA2DD;jsessionid=F648C088BD293070BD7A8D3AFC0F1FFA;jsessionid=6401FDF5ADBFA021AB742361E58CFA17;jsessionid=0EF8717F3CFA1ECD51B72897A5321E03;jsessionid=2F47A7FCA906E7BC236E7C39414853D6;jsessionid=74F93336FB1DF032C4EB950E1E247510 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A10F0BAC488BB1596C5F0CE4F667FB3F;jsessionid=4604EAF85061B7D2112CE838C4F764A6;jsessionid=F32A6229814EF0D0EEB5C0B14F6DA2DD;jsessionid=F648C088BD293070BD7A8D3AFC0F1FFA;jsessionid=6401FDF5ADBFA021AB742361E58CFA17;jsessionid=0EF8717F3CFA1ECD51B72897A5321E03;jsessionid=2F47A7FCA906E7BC236E7C39414853D6;jsessionid=74F93336FB1DF032C4EB950E1E247510